FRESENIUS SE+CO.KGAA O.N./ DE0005785604 /
8/19/2022 5:35:09 PM | Chg. +0.050 | Volume | Bid5:35:09 PM | Ask8/19/2022 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
24.620EUR | +0.20% | 1.26 mill. Turnover: 30.9 mill. |
-Bid Size: - | -Ask Size: - | 13.79 bill.EUR | 3.73% | 7.57 |
GlobeNewswire
6/11/2021
UPDATE -- Humacyte Expands Strategic Global Partnership with Fresenius Medical Care
GlobeNewswire
11/11/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medica...
GlobeNewswire
11/4/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medica...
GlobeNewswire
10/29/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Fresenius Medica...
GlobeNewswire
10/23/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medic...
GlobeNewswire
6/9/2017
KISSEI TO MARKET AVACOPAN IN JAPAN FOR VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
GlobeNewswire
1/27/2011
Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab®